Amneal Pharmaceuticals Inc (NYSE:AMRX) – Equities research analysts at Piper Jaffray Companies reduced their Q1 2020 earnings per share (EPS) estimates for Amneal Pharmaceuticals in a research note issued to investors on Wednesday, November 6th, according to Zacks Investment Research. Piper Jaffray Companies analyst D. Amsellem now anticipates that the company will earn $0.06 per share for the quarter, down from their previous forecast of $0.11. Piper Jaffray Companies also issued estimates for Amneal Pharmaceuticals’ Q2 2020 earnings at $0.08 EPS.
Several other research firms have also issued reports on AMRX. ValuEngine upgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, November 25th. JPMorgan Chase & Co. downgraded Amneal Pharmaceuticals from a “neutral” rating to an “underweight” rating in a report on Tuesday, November 12th. Leerink Swann lowered Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. SunTrust Banks restated a “buy” rating and set a $5.00 price target on shares of Amneal Pharmaceuticals in a research report on Tuesday, August 6th. Finally, Zacks Investment Research cut Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 23rd. Three analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. Amneal Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $9.00.
Shares of AMRX traded up $0.20 during mid-day trading on Monday, reaching $4.04. The company’s stock had a trading volume of 5,179,103 shares, compared to its average volume of 1,506,678. The stock has a market cap of $1.14 billion, a PE ratio of 4.25, a P/E/G ratio of 3.66 and a beta of 1.52. The company’s fifty day moving average price is $3.10 and its two-hundred day moving average price is $4.34. Amneal Pharmaceuticals has a 52 week low of $2.27 and a 52 week high of $18.17. The company has a current ratio of 2.25, a quick ratio of 1.50 and a debt-to-equity ratio of 6.91.
Amneal Pharmaceuticals (NYSE:AMRX) last issued its earnings results on Wednesday, November 6th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.09). The firm had revenue of $378.30 million during the quarter, compared to analysts’ expectations of $403.90 million. Amneal Pharmaceuticals had a positive return on equity of 23.17% and a negative net margin of 19.61%. The firm’s quarterly revenue was down 20.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.28 EPS.
Large investors have recently modified their holdings of the company. TPG Group Holdings SBS Advisors Inc. grew its stake in shares of Amneal Pharmaceuticals by 317.4% in the third quarter. TPG Group Holdings SBS Advisors Inc. now owns 16,213,367 shares of the company’s stock worth $47,019,000 after purchasing an additional 12,328,767 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Amneal Pharmaceuticals by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 9,757,628 shares of the company’s stock worth $69,962,000 after buying an additional 218,497 shares during the last quarter. BlackRock Inc. grew its position in shares of Amneal Pharmaceuticals by 9.4% in the 2nd quarter. BlackRock Inc. now owns 6,394,923 shares of the company’s stock worth $45,852,000 after buying an additional 549,217 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $23,772,000. Finally, Northern Trust Corp increased its stake in shares of Amneal Pharmaceuticals by 1.3% during the second quarter. Northern Trust Corp now owns 1,200,738 shares of the company’s stock valued at $8,609,000 after buying an additional 14,961 shares during the period. 35.80% of the stock is owned by hedge funds and other institutional investors.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Featured Article: How does a dividend reinvestment plan work?
Get a free copy of the Zacks research report on Amneal Pharmaceuticals (AMRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amneal Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
